Abstract
Introduction
This study evaluated the capability of silk fibroin (SF) and recombinant human bone morphogenetic protein-2 loaded SF (SF-BMP) as a bone defect replacement matrix when grafted in a calvarial bone defect of rats in vivo.
Materials and Methods
A total 70 calvarial critical size defects (5.0 mm in diameter) made on 35 adult female Sprague-Dawley rats were used in this study. The defects were transplanted with (1) rhBMP-2 loaded silk fibroin graft (SF-BMP: 0.8+10 μ g), (2) Silk fibroin (SF: 10 μ g), and (3) no graft material (Raw). The samples were evaluated with soft x-rays, alkaline phosphatase activity, calcium/phosphate quantification, histological and histomorphometric analysis at postoperative 4 and 8 weeks.
Results
The SF-BMP group (48.86±14.92%) had a significantly higher mean percentage bone area than the SF group (24.96±11.01%) at postoperative 4 weeks.(P<0.05) In addition, the SF-BMP group (40.01±12.43%) had a higher % bone area at postoperative 8 weeks than the SF group (33.26±5.15%). The mean ratio of gray scale levels to the host bone showed that the SF-BMP group (0.67±0.08) had a higher mean ratio level than the SF group (0.61±0.09) at postoperative 8 weeks. These differences were not statistically significant.(P=0.168 and P=0.243, respectively) The ratio of the calcium and phosphate contents of the SF-BMP (0.93±0.22) group was lower than that of the SF (1.90±1.42) group at postoperative 4 weeks. However, the SF-BMP group (0.75±0.31) had a higher Ca/PO4 ratio than the SF (0.68±0.04) at postoperative 8 weeks. These differences were not statistically significant.(P=0.126 and P=0.627, respectively) For the bone-specific alkaline phosphatase (ALP) activity, which is recognized as a reliable indicator of the osteoblast function, the SF-BMP (23.71±8.60 U/L) groups had a significantly higher value than the SF group (12.65± 6.47 U/L) at postoperative 4 weeks.(P<0.05) At postoperative 8 weeks, the SF-BMP (21.65±10.02 U/L) group had a lower bone-specific ALP activity than the SF group (16.72±7.35 U/L). This difference was not statistically significant.(P=0.263) For the histological evaluation, the SF-BMP group revealed less inflammation, lower foreign body reactions and higher bone healing than the SF group at postoperative 4 and 8 weeks. The SF group revealed more foreign body reactions at postoperative 4 weeks. However, this immunogenic reaction decreased and the remnant of grafted material was observed at postoperative 8 weeks. For histomorphometric analysis, the SF-BMP group had a significantly longer bone length to total length ratio than those of the SF group at postoperative 4 and 8 weeks.(P<0.05)
References
2. Mizutani H, Urist MR. The nature of bone morphogenetic protein (BMP) fractions derived from bovine bone matrix gelatin. Clin Orthop Relat Res. 1982. 213–23.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
3. Sato K, Urist MR. Bone morphogenetic protein-induced cartilage development in tissue culture. Clin Orthop Relat Res. 1984; 183:180–7.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
4. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: Molecular clones and activities. Science. 1988; 242:1528–34.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
5. Sampath TK, Reddi AH. Homolgy of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix. Proc Natl Acad Sci U S A. 1983; 80:6591–5.
6. Chai Y, Slavkin HC. Biology of bone induction and its clinical applications. Oral Maxillofac Surg Clin North Am. 1994; 7:739–53.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
7. Wozney JM. Biology and clinical applications of rhBMP-2. Lynch SE, Genco RJ, Marx RE, editors. Tissue engineering: applications in maxillofacial surgery and periodontics. Chicago: Quintessence;1999. p. 103–10.
8. Komaki M, Katagiri T, Suda T. Bone morphogenetic protein-2 does not alter differentiation pathway of committed progenitors of osteoblasts and chondroblasts. Cell Tissue Res. 1996; 284:9–17.
9. Nam JH, Park JC, Yu SB, Chung YI, Tae GY, Kim JJ, et al. Bone regeneration with MMP sensitive hyaluronic acid-based hydrogel, rhBMP-2 and nanoparticles in rat calvarial critical size defect (CSD) model. J Korean Assoc Oral Maxillofac Surg. 2009; 35:137–45.
10. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev. 2003; 55:1613–29.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
11. Lee JH, Kim SM, Park JC, Sung MA, Yu SB, Nam JH, et al. Bone regeneration with hyaluronic acid based hydrogel-nanoparticle complex and rhBMP-2 in rat critical size defect model. Tissue Eng Regen Med. 2009; 6:730–8.
12. Sakiyama-Elbert SE, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release. 2000; 65:389–402.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
13. Kim HD, Valentini RF. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J Biomed Mater Res. 2002; 59:573–84.
14. Chung YI, Ahn KM, Jeon SH, Lee SY, Lee JH, Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J Control Release. 2007; 121:91–9.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
15. Saito N, Okada T, Horiuchi H, Ota H, Takahashi J, Murakami N, et al. Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers. Bone. 2003; 32:381–6. s.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
16. Boyan BD, Lohmann CH, Somers A, Niederauer GG, Wozney JM, Dean DD, et al. Potential of porous poly-D,L-lactide-co-glycolide particles as a carrier for recombinant human bone morphogenetic protein-2 during osteoinduction in vivo. J Biomed Mater Res. 1999; 46:51–9.
17. Sung HJ, Meredith C, Johnson C, Galis ZS. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials. 2004; 25:5735–42.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
18. Dal Pra I, Freddi G, Minic J, Chiarini A, Armato U. De novo engineering of reticular connective tissue in vivo by silk fibroin nonwoven materials. Biomaterials. 2005; 26:1987–99.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
19. Horan RL, Antle K, Collette AL, Wang Y, Huang J, Moreau JE, et al. In vitro degradation of silk fibroin. Biomaterials. 2005; 26:3385–93.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
20. Gosline JM, DeMont ME, Denny MW. The structure and properties of spider silk. Endeavour. 1986; 10:37–43.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
21. Furuzono T, Ueki M, Kitamura H, Oka K, Imai E. Histological reaction of sintered nanohydroxyapatite-coated cuff and its fibroblast-like cell hybrid for an indwelling catheter. J Biomed Mater Res Part B Appl Biomater. 2009; 89:77–85.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
22. Wang Y, Blasioli DJ, Kim HJ, Kim HS, Kaplan DL. Cartilage tissue engineering with silk scaffolds and human articular chondrocytes. Biomaterials. 2006; 27:4434–42.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
23. Kirker-Head C, Karageorgiou V, Hofmann S, Fajardo R, Betz O, Merkle HP, et al. BMP-silk composite matrices heal critically sized femoral defects. Bone. 2007; 41:247–55.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
24. Karageorgiou V, Tomkins M, Fajardo R, Meinel L, Snyder B, Wade K, et al. Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J Biomed Mater Res A. 2006; 78:324–34.
25. Meinel L, Fajardo R, Hofmann S, Langer R, Chen J, Snyder B, et al. Silk implants for the healing of critical size bone defects. Bone. 2005; 37:688–98.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
26. Jang ES, Park JW, Kweon H, Lee KG, Kang SW, Baek DH, et al. Restoration of peri-implant defects in immediate implant installations by Choukroun platelet-rich-fibroin and silk fibroin powder combination graft. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109:831–6.
27. Lee EH, Kim JY, Kweon HY, Jo YY, Min SK, Park YW, et al. A combination graft of low-molecular-weight silk fibroin with Choukroun platelet-rich fibrin for rabbit calvarial defect. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109:e33–8.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
28. Kim JY, Choi JY, Jeong JH, Jang ES, Kim AS, Kim SG, et al. Low molecular weight silk fibroin increases alkaline phosphatase and type I collagen expression in MG63 cells. BMB Rep. 2010; 43:52–6.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
29. Minoura N, Tsukada M, Nagura M. Fine structure and oxygen permeability of silk fibroin membrane treated with methanol. Polymer. 1990; 31:265–9.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
30. Santin M, Motta A, Freddi G, Cannas M. In vitro evaluation of the inflammatory potential of the silk fibroin. J Biomed Mater Res. 1999; 46:382–9.
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Fig. 1.
Midsagittal reference line for histomorphometric analysis. A. Harvested calvaria, B. Soft X-ray image.
![jkaoms-36-366f1.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f1.gif)
Fig. 2.
% bone area of densitometric analysis. A. The SF-BMP group (48.86±14.92%) had a significant higher value than that of SF group (24.96±11.01%, *P<0.05) at postoperative 4 weeks. B. The SF-BMP group (40.01±12.43%) had a higher %bone area than that of SF group (33.26±5.15%) at postoperative 8 weeks. This difference was not, however, statistically significant.(P=0.168) (SF: silk fibroin, SF-BMP: recombinant human bone morphogenetic protein-2 loaded SF)
![jkaoms-36-366f2.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f2.gif)
Fig. 3.
Gray scale ratio to host bone. A. The SF-BMP group (0.70±0.07) and SF group (0.70±0.09) had a higher value than that of the Raw group (0.67±0.12) at postoperative 4 weeks. These differences were not, however, statistically significant.(P=0.418 and P=0.424, respectively) B. At postoperative 8 weeks, the SF-BMP group (0.67±0.08) had a higher value than that of the SF group (0.61±0.09), however, it was not statistically significant.(P=0.243) (SF: silk fibroin, SF-BMP: recombinant human bone morphogenetic protein-2 loaded SF)
![jkaoms-36-366f3.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f3.gif)
Fig. 4.
ALP activity. A. The SF-BMP group (23.71±8.60 U/L) had a significant higher value than that of the SF group (12.65± 6.47 U/L) at postoperative 4 weeks.(*P<0.05) B. The SF-BMP group (21.65±10.02 U/L) had a higher value than that of the SF group (16.72±7.35 U/L) at postoperative 8 weeks. However, there was not statistically significant difference.(P=0.263) (ALP: alkaline phosphatase, SF: silk fibroin, SF-BMP: recombinant human bone morphogenetic protein-2 loaded SF)
![jkaoms-36-366f4.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f4.gif)
Fig. 5.
Ca2+ quantification. A. The SF-BMP group (28.67±14.28 mg/dL) had a significant higher value than that of the SF group (12.53±5.01 mg/dL) at postoperative 4 weeks.(*P<0.05) B. The SF-BMP group (28.56±20.44 mg/dL) had a significant higher value than that of the SF group (2.83±1.38 mg/dL) at postoperative 8 weeks.(*P<0.05) (SF: silk fibroin, SF-BMP: recombinant human bone morphogenetic protein-2 loaded SF)
![jkaoms-36-366f5.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f5.gif)
Fig. 6.
PO42- quantification. A. The SF-BMP group (30.77±12.52 mg/dL) had a significant higher value than that of the SF group (12.28±11.87 mg/dL) at postoperative 4 weeks.(*P<0.05) B. The SF-BMP group(34.09±12.37 mg/dL) had a significant higher value than that of the SF group (4.25±2.34 mg/dL)at postoperative 8 weeks.(*P<0.05) (SF: silk fibroin, SF-BMP: recombinant human bone morphogenetic protein-2 loaded SF)
![jkaoms-36-366f6.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f6.gif)
Fig. 7.
A. Postoperative 4 weeks.(H&E staining, original magnification x100) B. Postoperative 8 weeks.(H&E staining, original magnification x100) C. Postoperative 4 weeks.(Masson's trichrome staining, original magnification x100) D. Postoperative 8 weeks.(Masson's trichrome staining, original magnification x100) E. Postoperative 4 weeks.(Osteocalcin immunoreactive staining, original magnification x100) F. Postoperative 8 weeks.(Osteocalcin immunoreactive staining, original magnification x100)(rhBMP-2: recombinant human bone morphogenetic protein-2, SF: silk fibroin, SF-BMP: recombinant human bone morphogenetic protein-2 loaded SF)
![jkaoms-36-366f7.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f7.gif)
Fig. 8.
A. Postoperative 4 weeks.(H&E staining, original magnification x100) B. Postoperative 8 weeks.(H&E staining, original magnification x100) C. Postoperative 4 weeks.(Masson's trichrome staining, original magnification x100) D. Postoperative 8 weeks.(Masson's trichrome staining, original magnification x100) E. Postoperative 4 weeks.(Osteocalcin immunoreactive staining, original magnification x100) F. Postoperative 8 weeks.(Osteocalcin immunoreactive staining, original magnification x100)(rhBMP-2: recombinant human bone morphogenetic protein-2, SF: silk fibroin)
![jkaoms-36-366f8.tif](/upload/SynapseXML/0070jkaoms/thumb/jkaoms-36-366f8.gif)
Table 1.
Animal grouping
Groups | N (sites/animals) | Composition | Graft | |
---|---|---|---|---|
4 weeks | 8 weeks | |||
SF-BMP | 12 (6) | 10 (6) | rhBMP-2 loaded silk fibroin | 0.8+10 μ g |
SF | 12 (6) | 12 (6) | Silk fibroin | 10 μ g |
Raw | 12 (6) | 12 (5) | Raw defect | None |
Table 2.
Dry weight
Groups | 4 weeks (mg) | 8 weeks (mg) |
---|---|---|
SF-BMP | 635.83±21.09 | 32.17±23.05 |
SF | 611.75±4.03 | 7.00±2.83 |
Raw | 616.83±13.35 | 28.17±13.47 |